Bioject Medical Technologies
Bioject Medical Technologies, founded in 1985 in Tigard, Oregon, develops proprietary needle-free jet injection systems intended to administer liquid medications and vaccines without hypodermic needles, targeting chronic disease patients and pharmaceutical partners.
- Company typePrivate
- Founded1985
- HeadquartersTigard, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Bioject Medical Technologies does
Bioject Medical Technologies is a US-based, privately held medical device company founded in 1985 and headquartered in Tigard, Oregon. The company develops needle-free jet injector technology intended to administer liquid medications — including vaccines — without a traditional hypodermic needle, targeting the pain, needle phobia, and infection-risk drawbacks of needle-based delivery. The stated functional benefits center on painless drug administration and improved self-administration for chronic disease patients who require regular injections.
The underlying technology is proprietary needle-free jet injection, a mechanical modality rather than a software or analytical platform. No public information on the product portfolio (specific device models, SKU structure, or technical specifications), regulatory clearances, manufacturing footprint, or go-to-market mechanics was present in the supplied data. There is no disclosed pricing model, no named marketing or distribution channels, no published partner or licensee list, and no management team detail available.
Capital formation has been limited: the company has raised approximately $3.88 million across five disclosed rounds between 2006 and 2013, with Partners for Growth participating as a repeat lender in the two earliest rounds. There has been no disclosed financing activity since October 2013. The company's web property currently serves only a generic security challenge page rather than active commercial content, and no operating status, revenue, or employee-count confirmations are available in the input beyond a 11-50 headcount band. Taken together, the data picture is of a legacy device company whose current commercial activity is unverifiable.
Bioject Medical Technologies firmographics
Firmographics- Name
- Bioject Medical Technologies
- Website
- https://bioject.com
- Company type
- Private
- Founded year
- 1985
- Headcount range
- 11–50 employees
- Short description
- Bioject Medical Technologies, founded in 1985 in Tigard, Oregon, develops proprietary needle-free jet injection systems intended to administer liquid medications and vaccines without hypodermic needles, targeting chronic disease patients and pharmaceutical partners.
- Ownership category
- akta.pro rank
Bioject Medical Technologies industry classification
Industry- Product category
- Drug Delivery Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Needle-Free Injection Systems (Jet Injectors/Microneedle Patches) (HLAHAIAD)
- akta.pro secondary industry
- Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF)
Keywords
Where Bioject Medical Technologies is headquartered
LocationHeadquarters
- HQ city
- Tigard
- HQ country
- United States
- HQ region
- North America
Markets served
Bioject Medical Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations
Bioject Medical Technologies product offering
Product offeringCore offering
Bioject Medical Technologies develops and commercializes needle-free injection therapy systems that deliver liquid medications such as vaccines using a proprietary jet-injector mechanism instead of a hypodermic needle. The technology targets clinical administration and self-administration settings where eliminating needles improves safety, patient comfort, and sharps-waste handling.
Differentiator
Problem solved
Functional benefit
Products and services
- Needle-Free Jet Injector System
Companies that use Bioject Medical Technologies
Customer profileIdeal customer profiles1 record
Bioject Medical Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Bioject Medical Technologies partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights2 records
Bioject Medical Technologies competitors and assessment
Company assessmentBroad incumbents
- Becton, Dickinson and Company (BD): BD is a dominant broad incumbent in prefilled syringes, safety syringes, and auto-injector devices — the main line of competition for any needle-free drug delivery company.
- Stevanato Group: Stevanato supplies integrated drug containment, delivery devices, and prefilled syringe systems for pharma/biologic customers, competing upstream of Bioject in vaccine and injectable delivery hardware.
- West Pharmaceutical Services: West supplies containment and delivery components (including devices for injectables) used by biologics and vaccine manufacturers, overlapping with Bioject's drug delivery and vaccine administration value proposition.
- Antares Pharma (now part of Halozyme): Antares Pharma (acquired by Halozyme) was a long-standing player in self-injection devices including jet injectors and pen platforms, sharing Bioject's space in home drug-delivery hardware.
Direct peers
- PharmaJet: PharmaJet is a direct competitor developing needle-free jet injection devices for vaccines and biologics, addressing the same needle-phobia and self-administration use cases as Bioject.
- INJEX Pharma (Injex Industries): INJEX markets a needle-free jet injector system for insulin and other injectables, competing head-on with Bioject's needle-free liquid medication delivery platform.
- Zogenix (now Lundbeck's Modis): Zogenix developed injectable drug-delivery platforms including needle-free administration technologies, situating it as a direct comparable to Bioject's jet injector approach.
Emerging players
- Vaxxas: Vaxxas develops high-density microarray patches for vaccine delivery, directly competing in the needle-free and pain-free vaccine administration segment Bioject addresses.
- Insulet Corporation: Insulet's wearable patch-based drug delivery (Omnipod) addresses needle-averse patients requiring repeated self-administration, an adjacent take on Bioject's needle-free self-injection thesis.
- Enable Injections: Enable Injections develops wearable, large-volume subcutaneous delivery systems for biologics, competing for the same self-administration and infusion use cases Bioject targets with jet injection.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights4 records
Customer concentration
Bioject Medical Technologies social profiles
Digital presenceBioject Medical Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bioject Medical Technologies leadership team
Management profileNumber of profiles
Bioject Medical Technologies funding detail
Funding detailFunding overview
Funding rounds5 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bioject Medical Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bioject Medical Technologies
What does Bioject Medical Technologies do?
Bioject Medical Technologies develops and commercializes needle-free injection therapy systems that deliver liquid medications such as vaccines using a proprietary jet-injector mechanism instead of a hypodermic needle. The technology targets clinical administration and self-administration settings where eliminating needles improves safety, patient comfort, and sharps-waste handling.
When was Bioject Medical Technologies founded?
Bioject Medical Technologies was founded in 1985. It employs 11 to 50 people.
Where is Bioject Medical Technologies based?
Bioject Medical Technologies is headquartered in Tigard, United States, in the North America region.
Who are Bioject Medical Technologies's main competitors?
Broad incumbents on record are Becton, Dickinson and Company (BD), Stevanato Group, West Pharmaceutical Services and Antares Pharma (now part of Halozyme). Direct peers are PharmaJet, INJEX Pharma (Injex Industries) and Zogenix (now Lundbeck's Modis). Emerging players are Vaxxas, Insulet Corporation and Enable Injections.
Does Bioject Medical Technologies have an API?
No public API is recorded for Bioject Medical Technologies.
What industry is Bioject Medical Technologies in?
Bioject Medical Technologies's product category is Drug Delivery Devices. Its primary akta.pro industry code is HLAHAIAD, Needle-Free Injection Systems (Jet Injectors/Microneedle Patches), with a secondary code of HLAAAEAF, Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral). Its NAICS code is 339112 and its SIC code is 3841.